Conclusion
In vitro data and clinical studies have demonstrated that GM-CSF reverses granulocytopenia in patients. In animal studies, it also augments the fungicidal activity of neutrophils and monocyte/macrophages. This in vitro effect may correlate with demonstrated clinical benefit, although further studies to determine optimal dosage, and route and time of administration are required. The promising results of the studies carried out to date indicate that this is an area which merits further investigation.
References
Vartivarian S, Smith CB Pathogenesis, host resistance, and predisposing factors. In: Bodey GP (ed): Candidiasis: pathogenesis, diagnosis, and treatment. Raven Press, New York, 1992, p. 59–84.
Anaissie E Opportunistic mycoses in the immunocompromised host: experience at a cancer centre and review. Clinical Infectious Diseases 1992, 14, Supplement 1: S43-S53.
Meyers JD Fungal infections in bone marrow transplant patients. Seminars in Oncology 1990, 17, Supplement 6: 10.
Bodey GP Fungal infections complicating acute leukemia. Journal of Chronic Diseases 1966, 19: 667–687.
Bodey GP, Buckley M, Sathe YS, Freireich EJ Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966, 64: 328–340.
Bender BS, Bohnsack JF, Sourlis SH Demonstration of defective C3 receptor mediated clearance by the reticuloendothelial system in patients with acquired immunodeficiency syndrome. Journal of Clinical Investigation 1987, 79: 715–720.
Baldwin GC, Gasson J, Quan SG, Fleischmann J, Weisbart R, Oette D, Mitsuyasu RT, Golde D GM-CSF enhances neutrophil function in AIDS patients. Proceedings of the National Academy of Sciences 1988, 85: 2763–2766.
Scadden DT GM-CSF in AIDS. Infection 1992, 20, Supplement: 103–106.
Lehrer RI, Cline MJ Leukocyte candidacidal activity and resistance to systemic candidiasis in patients with cancer. Cancer 1971, 27: 1211–1217.
Bodey GP, Vartivarian S Aspergillosis. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 413–437.
Schaffner A, Douglas H, Braude A Selective protection againstConidia by mononuclear and againstMycelia by polymorphonuclear phagocytes in resistance toAspergillus. Journal of Clinical Investigation 1982, 69: 617–619.
Bodey GP Hematogenous and major organ candidiasis. In: Bodey GP (ed): Candidiasis: pathogenesis, diagnosis, and treatment. Raven Press, New York, 1992, p. 279–329.
Bodey GP Candidiasis in cancer patients. In: Bodey GP: Candidiasis: a growing concern. American Journal of Medicine 1984, 77: 13–19.
Advani R, Chao NJ, Horning SJ, Blume KG, Ahn DK, Lamborn KR, Fleming NC, Bonnem EM, Greenberg PL Granulocyte macrophage colony stimulating factor as an adjunct to autologous hemopoietic stem cell transplantation. Annals of Internal Medicine 1992, 116: 183–189.
Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner CD, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New England Journal of Medicine 1991, 324: 1773–1778.
Nemunaitis J Granulocyte-macrophage colony stimulating factor: a review from pre-clinical development to clinical application. Transfusion 1993, 33: 70–83.
Reed S Macrophage activation and inactivation in protozoal infections, van Furth R (ed): Hemopoietic growth factors and mononuclear phagocytes. Karger, Basel, 1993, p. 98–110.
Mayer P, Schutze E, Lam C, Kricek F, Leihl E Recombinant murine granulocyte-macrophage colony stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. Journal of Infectious Diseases 1991, 163: 584–590.
Smith PD, Lamerson CL, Banks SM Granulocyte-macrophage colony stimulating factor augments human monocyte fungicidal activity. Journal of Infectious Diseases 1990, 161: 999–1005.
Spielberger R, Falleroni MJ, Coene AJ, Larson RA Concomitant amphotericin B therapy, granulocyte transfusions and GM-CSF administration for disseminated infection withFusarium in a granulocytopenic patient. Clinical Infectious Diseases 1993, 16: 528–530.
Klausmann M, Pfluger KH, Krumwieh D, Seiler FR, Havemann K Modulation of functions of granulocytes by rhGM-CSF and possible complications of GM-CSF therapy. Leukemia 1988, 2, Supplement: 63–72.
Addison IE, Johnson B, Devereux S, Goldstone AH, Linch DG Granulocyte-macrophage colony stimulating factor can inhibit neutrophil migration in vivo. Clinician and Experimental Immunology 1989, 76: 149–153.
Montgomery B, Bianco JA, Jacobsen A Localization of neutrophils to the site of infection during treatment with rGM-CSF and pentoxifylline. Blood 1991, 78: 533–534.
Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clinical Infectious Diseases 1993, 17: 705–707.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bodey, G.P. The potential role of granulocyte-macrophage colony stimulating factor in therapy of fungal infections: A commentary. Eur. J. Clin. Microbiol. Infect. Dis. 13, 363–366 (1994). https://doi.org/10.1007/BF01971991
Issue Date:
DOI: https://doi.org/10.1007/BF01971991